title: Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?
authors.forename: Vasilios G
authors.initials: VG
authors.lastname: Athyros
authors.forename: Niki
authors.initials: N
authors.lastname: Katsiki
authors.affiliation: Dept. of Clinical Biochemistry (Vascular Disease Prevention Clinics) Royal Free Hospital campus, University College London Medical School University College London (UCL), Pond Street, London NW3 2QG, UK. MIKHAILIDIS@aol.com.
authors.forename: Dimitri P
authors.initials: DP
authors.lastname: Mikhailidis
mesh_terms: D004359:Drug Therapy, Combination / Q000379:methods; D005234:Fatty Liver / Q000188:drug therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D000069450:Liraglutide / Q000627:therapeutic use*; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D000069450:Liraglutide